ORPHA:69736
Bilateral acute depigmentation of the iris
Also known as: BADI
Publications
44
45.7th percentile
Trials
0
Interventional, condition-specific
Researchers
158
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
Bilateral acute depigmentation of the iris (BADI) is characterized by acute onset of bilateral iris depigmentation, pigment dispersion in the anterior chamber, and heavy pigment deposition in the anterior chamber angle. Patients typically present with acute and usually severe photophobia, blurred vision, red eye, and ocular discomfort or pain with a usually self-limiting clinical course. Cases often occur after a flu-like illness, upper respiratory tract infection, and after the use of oral moxifloxacin. When associated with iris epithelial depigmentation, iris transillumination defects and atonic/mydriatic pupil, the condition is referred to as bilateral acute iris transillumination (BAIT) which has an increased risk of severe intractable rise in intraocular pressure.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019074
- UMLS:C4304058
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
44 matched papers (33 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
44
44 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
44 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
33 in the last 10 years · medium confidence · 45.7th percentile (publications denominator)
Phrase hits: 44 · MeSH hits: 0
Who's working on it?
158
Distinct author names in 44 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Maestrini HA3 papers · 2022
Glaucoma Service, Oculare Ophthalmology Center, Belo Horizonte, Brazil. heloisa.maestrini@gmail.com
Papers in Europe PMC - 02Tugal-Tutkun I3 papers · 2023
Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. itutkun@istanbul.edu.tr
Papers in Europe PMC - 03Berker N2 papers · 2018
Ankara Ulucanlar Eye Training and Research Hospital, Ankara, Turkey.
Papers in Europe PMC - 04Gershkovich A2 papers · 2020
Harkness Eye Institute, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Papers in Europe PMC - 05Gonul S2 papers · 2022
Department of Ophthalmology, Selcuk University Faculty of Medicine, Konya, Turkey.
Papers in Europe PMC - 06Langevin S2 papers · 2020
Harkness Eye Institute, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Papers in Europe PMC - 07Maestrini AA2 papers · 2022
Department of Glaucoma, Oculare Hospital de Oftalmologia, Belo Horizonte, MG, Brazil.
Papers in Europe PMC - 08Mahendradas P2 papers · 2019
Uveitis and Ocular Immunology Department, Narayana Nethralaya, Bangalore. Electronic address: m.padmamalini@gmail.com.
Papers in Europe PMC - 09Marr BP2 papers · 2020
Harkness Eye Institute, Columbia University Irving Medical Center, New York, NY, 10032, USA. BPM2133@cumc.columbia.edu.
Papers in Europe PMC - 10Shetty R2 papers · 2019
Department of corneal and refractive surgery, Narayana Nethralaya, Bangalore.. Electronic address: drrohitshetty@yahoo.com.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Bilateral acute depigmentation of the iris" OR "Bilateral acute depigmentation of iris"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Bilateral acute depigmentation of the iris" OR "Bilateral acute depigmentation of iris"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: BADI
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T01:29:48.867Z